Open AccessStatin‐induced autoimmune hepatitis in patients with type 1 diabetes: A report of two cases and literature review
Author(s) -
Kawasaki Eiji,
Fukuyama Takahiro,
Kuriyama Erisa,
Uchida Aira,
Sagara Yoko,
Tamai Hidekazu,
Nakano Yuko,
Tojikubo Masayuki,
Koga Nobuhiko
Publication year - 2020
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.13271
Subject(s) - medicine , rosuvastatin , autoimmune hepatitis , statin , liver biopsy , discontinuation , hepatitis , type 2 diabetes , prednisolone , diabetes mellitus , metformin , gastroenterology , atorvastatin , hydroxychloroquine , biopsy , disease , endocrinology , covid-19 , infectious disease (medical specialty)
Statins are widely used medications for the treatment of hypercholesterolemia, as well as prevention of cardiovascular disease. We report two patients with type 1 diabetes who developed autoimmune hepatitis after the administration of statin. The first patient developed the marked elevation of liver enzymes 6 months into atorvastatin therapy. The second patient developed liver dysfunction 8 months after the initiation of rosuvastatin therapy. Liver biopsies in both patients showed either portal, interface and lobular hepatitis or a piece‐meal necrosis with lymphocytes and plasma cell infiltration that were compatible with autoimmune hepatitis. Then, both patients were started on prednisolone, to which they responded well. Liver biopsy is to be considered for type 1 diabetes patients if there is no improvement of liver dysfunction after discontinuation of statins.